Most non-Hodgkin's lymphomas (NHL) initially respond to chemotherapy, but relapse is common and treatment is often limited by chemotherapy-related toxicity. Bortezomib, is a highly selective proteasome inhibitor with anti-NHL activity; it is currently FDA approved for second-line treatment of mantle cell lymphoma (MCL). Bortezomib exerts its activity in part through the generation of reactive o...

Non-Hodgkin's lymphoma (NHL) represents a diverse group of hematologic malignancies originating in B or T lymphocytes. Approximately 85% of NHLs are of B-cell origin, with the remainder mostly of T-cell origin. The most common NHL types are diffuse large B-cell lymphoma (31%) and follicular lymphoma (22%). More than 65,000 new cases of NHL develop each year, and approximately 20,000 people with...

lymphomas are classified as hodgkin’s and non-hodgkin’s lymphomas (hl nhl) nhl being further sub-divided into b, t and null cell categories on the basis of who classification. with a few exceptions worldwide, b-nhl are more common, accounting approximately 80-85% of all cases of nhl compared to t-nhl, which accounts for about 10-15% of all nhl cases. the incidence of nhl has shown a steady incr...

Allogeneic hematopoietic cell transplantation (alloHCT) used to play a defined role in the treatment of non-Hodgkin lymphoma (NHL). With advent modern targeted molecular therapies and immunotherapies, standards at least for B-cell have undergone significant changes, thereby questioning traditional alloHCT these diseases. This paper attempts describe current place perspectives rapidly evolving l...

Background. Aberrant methylation of checkpoint with forkhead and ring finger domains (CHFR) was found in B-cell non-Hodgkin lymphoma (NHL), whereas its role carcinogenesis is not clear. CHFR can control poly (ADP-ribose) polymerase levels by causing degradation. The study aimed to explore the roles mechanisms pathogenesis NHL. Methods. Short hairpin ribonucleic acid (ShRNAs) targeting 1 (PARP-1...

background: various infectious agents like ebstein barr virus (ebv), htlv-1 and helicobacter pylori have known as etiologic factors in different sub-types of lymphoma. although hepatitis c virus (hcv) has not only been important for its hepatotropism and hepatitis development, but also in recent years its association with some forms of non- hodgkin’s lymphoma (nhl), especially b cell nhl, has r...

We have previously shown that Salmonella immunotherapy is effective to treat B-cell non-Hodgkin lymphoma (B-NHL) in mice. However, this model involves animals with high tumor burden, whereas in the clinics B-NHL patients are usually treated with chemotherapy (CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone) as first-line therapy prior to immunotherapy. Recently, we have describ...

Cell lines are key tools in cancer research allowing the generation of neoplasias in animal models resembling the initial tumours able to mimic the original neoplasias closely in vivo. Canine lymphoma is the major hematopoietic malignancy in dogs and considered as a valuable spontaneous large animal model for human Non-Hodgkin's Lymphoma (NHL). Herein we describe the establishment and character...

Lenalidomide is an oral non-chemotherapy immunomodulator with direct and indirect effects on non-Hodgkin lymphoma (NHL) cells and with single-agent activity in relapsed/refractory aggressive and indolent B-cell NHL, including mantle cell lymphoma (MCL), diffuse large B-cell lymphoma, and follicular lymphoma. Based on the pivotal phase II MCL-001 trial of lenalidomide in heavily pretreated patie...

background: prostate cancer is one of the leading causes of cancer deaths among men. new gene expressed in prostate (ngep), is a prostate-specific gene expressed only in normal prostate and prostate cancer tissue. because of its selective expression in prostate cancer cell surface, ngep is a potential immunotherapeutic target. to target the ngep in prostate cancer, it is essential to investigat...